I’m finally through uploading the transcripts from almost all** of the CMS patient-focused listening sessions around the 10 drugs slated for price controls under the Inflation Reduction Act. You can
There’s a lot to go through this morning. Let’s get at it. I’m thinking about rare diseases this morning for a couple of reasons. First, there is this JAMA Internal
I’ve been on the record for a while now arguing that the conversation around obesity medicines ought not be a debate about whether the medicines are “worth it” -- it
I love Thanksgiving for a number of reasons, the two biggest of which are 1) pie and 2) the explicit focus on gratitude. This year, I’ve been especially fortunate. As
So I wasn’t gone that long, but I feel like I missed a ton. Eschewing the usual format in favor of some quick hits, grouped by importance. BIG DEALS The
My goal for The Arc is to have some sort of a spin on some element of the news, rather than just a Chat-GPT-sounding summary of whatever tabs I have
Generally, I try to reserve Inflection Point for breaking news, and it’s tough to justify highlighting a Wall Street Journal editorial in this slot. Bear with me. The WSJ editorial
Programming Note: Cost Curve will be off Thursday, Friday, and next Monday so that I can watch my social media manager/future Terrier do her thing against some of Canada’s best
The PhRMA Medicines in Development reports are almost hard to read because it’s hard to wrap your head around some of the numbers. The latest from the group looks at
Look, you’ve all seen the news, so I probably don’t need to provide the details: Lilly won FDA approval for Zepbound in obesity. It’s the same ingredient in Mounjaro and